Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with our previously announced plan to reduce general and administrative (G&A) expenses to optimize capital allocation across the organization. The restructuring includes a redesign of Pharming’s organizational structure and a 20% net reduction in non-c ...

If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on positive data from multinational Phase III study in children aged 4 to 11 years with APDSPDUFA target action date of January 31, 2026 Leiden, the Netherlands, October 1, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administr ...

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.Shares of Concentrix Corporation (NASDAQ: CNXC) fell sharply in pre-market trading after the company reported worse-than-expected third-quarter adjusted EPS results and cut its FY25 adjusted EPS guidance below estimates.Concentrix reported quarterly earnings of $2.78 per share, which missed the Street estimate of $2.86. Quarterly revenue came in at $2.48 billion, which beat the analyst consensus estimate of $2.45 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [2] Core Insights - The CXO industry is experiencing a recovery in market conditions, driven by improvements in supply-demand dynamics and a rebound in financing activities for innovative drugs [3][4] - The CDMO sector continues to show high growth potential, with leading companies improving their performance and expanding into emerging markets [5][6] - The CRO sector is approaching a turning point, with signs of demand recovery and improved order conditions [6][7] Summary by Sections CXO Industry Overview - The CXO industry operates on a "water seller" business model, closely tied to the financing of the biopharmaceutical sector. In the first eight months of 2025, overseas innovative drug financing reached $22.6 billion, a year-on-year decline of approximately 36%, while domestic innovative drug financing amounted to $7.75 billion, a year-on-year increase of about 89% [3][31] - The leading companies in the CXO sector are expected to enter an expansion phase as demand recovers, while smaller companies may face increased competition and exit the market [4][44] CDMO Sector - CDMO leading companies have begun to see marginal improvements in performance since Q4 2024, attributed to high overseas revenue and a unique business model that supports project pipeline growth [5][46] - The order situation for CDMO companies has improved significantly, with notable increases in backlogged orders for major players like WuXi AppTec and WuXi Biologics [49][50] - The CDMO business model is characterized by strong customer retention and project scalability, allowing for sustained growth despite challenges in new project signings [52] CRO Sector - The CRO sector is witnessing a divergence in performance among leading companies, with some starting to recover. The overall order situation has shown improvement, indicating a potential demand revival [6][22] - The price increase of experimental monkeys suggests a forthcoming recovery in preclinical CRO demand, highlighting the importance of resource availability for leading CRO companies [6][24] - The integration of AI in drug development processes is expected to enhance efficiency and reduce costs, with many domestic CRO leaders already adopting AI technologies [7][18] Recommended Companies - The report suggests focusing on key players in the CXO sector, including WuXi AppTec, WuXi Biologics, WuXi AppTec, and others, which are positioned well for growth based on their business characteristics and market trends [8][10]

Summary of Pharming Group FY Conference Call Company Overview - **Company**: Pharming Group (NasdaqGM:PHAR) - **CEO**: Fabrice Chouraqui - **Date of Conference**: September 08, 2025 Key Points Company Transformation - Pharming has evolved from a one-asset company with RUCONEST to a company with two commercial assets: RUCONEST and Joenja, both experiencing double-digit growth [2][3] - The company has a high-value pipeline with two programs projected to have sales potential exceeding $1 billion [2] Financial Performance - Sales grew by 26% in the last quarter, driven by RUCONEST and Joenja [4] - Revenue guidance for the year has been raised to between $335 million and $350 million [4] RUCONEST - RUCONEST is a cornerstone treatment for hereditary angioedema, with 97% of attacks treated with one dose and 93% of attacks stopped for at least three days [5][6] - The drug has been on the market for 10 years and is growing at a rate of 28% year-on-year [6] - RUCONEST's unique manufacturing process from transgenic rabbits makes it difficult to replicate [7] Joenja - Joenja is indicated for activated PI3K delta syndrome (APDS) and has shown significant patient uptake, with more new patients in the first half of the year than in the entire previous year [10][11] - Three growth catalysts for Joenja include: 1. Reclassification of VUS patients, with an estimated 20% of VUS patients potentially reclassified as APDS [12][13] 2. Expansion of the label to pediatric patients, with an NDA submitted to the FDA [14] 3. Geographic expansion, including recent launches in the UK and an NDA filed in Japan [15] Pipeline and Future Prospects - Pharming is studying Joenja's efficacy in adjacent indications, which could significantly broaden its market potential [16][17] - KL1333, acquired from Ableva, is being developed for primary mitochondrial disease, with a Phase 2 registrational trial ongoing [18][19] - The company aims to self-fund the development of its pipeline and launch of new drugs, leveraging cash flows from RUCONEST [20] Growth Outlook - The company has raised its revenue guidance and expects continued strong growth, with significant short-term catalysts for both Joenja and KL1333 [21][22] Additional Insights - The company is focused on creating a world leader in rare diseases, leveraging its capabilities in clinical development, supply chain, and commercial operations [3] - The strong performance of RUCONEST is critical for funding the expansion of the portfolio and pipeline [20]

Core Points - Pharming Group N.V. will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025 [1] - CEO Fabrice Chouraqui is scheduled to present on September 8 at 1:30pm EDT/19:30 CEST [1] - A live webcast and replay of the presentation will be available on Pharming's website [1] Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing innovative medicines for patients with rare and life-threatening diseases [3] - The company is headquartered in Leiden, the Netherlands, and operates in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific [3]

Core Viewpoint - Pharming Group N.V. has appointed Kenneth Lynard as Chief Financial Officer, effective October 1, 2025, to strengthen its financial leadership and support its growth strategy [1][2][3] Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for patients with rare and life-threatening diseases [5] - The company is headquartered in Leiden, the Netherlands, and operates in over 30 markets globally [5] Appointment Details - Kenneth Lynard brings over 20 years of experience in the life sciences industry, with a strong background in financial and operational transformation [2][3] - His previous roles include CFO positions at Schoeller Allibert, Zentiva, and Affidea, as well as senior leadership at Gilead Sciences, where he contributed to significant business growth [3][4] Leadership Perspective - CEO Fabrice Chouraqui expressed enthusiasm about Lynard's appointment, highlighting his extensive finance leadership capabilities and operational experience in both the U.S. and EU [3] - Lynard emphasized his commitment to Pharming's mission of serving patients with rare diseases and his focus on operational efficiency and sustainable value creation [4]

Pharming Group N.V. Sponsored ADR (PHAR) closed the last trading session at $12.66, gaining 24.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $30.67 indicates a 142.3% upside potential.The average comprises three short-term price targets ranging from a low of $14.00 to a high of $41.00, with a standard deviation of $14.57. While the lowest estimate indicates an increase of 10.6 ...

Shares of Pharming Group N.V. Sponsored ADR (PHAR) have gained 17.9% over the past four weeks to close the last trading session at $12.48, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $30.67 indicates a potential upside of 145.8%. The average comprises three short-term price targets ranging from a low of $14.00 to a high of $41.00, with a standard deviation of $14.57. While t ...

Group 1 - Pharming Group N.V. will participate in the Canaccord Genuity 45 Annual Growth Conference in Boston, USA, on August 12-13, 2025 [1] - CEO Fabrice Chouraqui will present on August 12 at 12:00pm EDT/18:00 CEST [1] - Investors can schedule one-to-one meetings with Pharming's management team through the Investor Relations team [1] Group 2 - Pharming Group N.V. is a global biopharmaceutical company focused on patients with rare, debilitating, and life-threatening diseases [2] - The company is involved in the commercialization and development of innovative medicines, including small molecules and biologics [2] - Pharming is headquartered in Leiden, the Netherlands, and operates in over 30 markets worldwide [2]